Rising Use of GLP-1 Drugs Benefits Eli Lilly
Gallup reports that the use of GLP-1 drugs for weight loss has increased significantly, from 3% in 2024 to 11% currently. This surge benefits pharmaceutical companies like Eli Lilly and Novo Nordisk, with Eli Lilly seeing particularly strong performance due to its best-selling drug tirzepatide (Mounjaro/Zepbound). In Q1, Mounjaro generated $8.7 billion in sales while Zepbound earned $4.2 billion.
Topics: Eli Lilly Foundayo GLP-1 drugs Mounjaro weight loss medications Zepbound